2024-516738-36-00
Not yet recruiting
Phase 1
INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)2 sites in 1 country21 target enrollmentStarted: October 8, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Not yet recruiting
- Enrollment
- 21
- Locations
- 2
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Dr. E.V.E. Madsen
Scientific
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Intraperitoneal and intravenous paclitaxel plus S-1 (Intraperitoneal and intravenous paclitaxel plus S-1)jRCTs06118000850
Recruiting
Phase 2
Intraperitoneal and intravenous paclitaxel plus S-1Gastric cancer with peritoneal metastasis or positive peritoneal cytology.JPRN-jRCTs061180008Fujiwara Yoshiyuki50
Not yet recruiting
Not Applicable
Phase 3 study of Paclitaxel therapy and monolithic systemic chemotherapy in patients with gastric cancer and gastroesophageal border cancer with peritoneal metastasisNeoplasmsKCT0009110Koera University Guro Hospital117
Not yet recruiting
Not Applicable
Treatment of abdominal mesothelioma with intra-abdominal chemotherapy - INTERACT MESONL-OMON26729one21
Recruiting
Not Applicable
Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety StudyNL-OMON56619Erasmus MC, Universitair Medisch Centrum Rotterdam21